Lupisit D: A Dual Action Treatment for Type 2 Diabetes

Lupisit D is a once-daily combination tablet containing Dapagliflozin (5mg) and Sitagliptin (50mg). These two medications work together to effectively manage type 2 diabetes by improving blood sugar control.

Dapagliflozin: A SGLT2 inhibitor that blocks glucose reabsorption in the kidneys, leading to increased glucose excretion in urine and reduced blood glucose levels.
Sitagliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels, promoting insulin secretion from beta cells and reducing glucagon release from alpha cells.

Lupisit D offers a convenient single-dose solution for individuals managing their type 2 diabetes. It's important to note that this medication may not be suitable for everyone. Always consult with your healthcare provider before starting any new treatment regimen.

Please remember: This description is intended for informational purposes only and does not constitute medical advice. Consult with a healthcare professional for personalized guidance regarding your individual health needs.